Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.48 |
| ▸ | NAMPT | P43490 | 10/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | KDM1A | O60341 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23826942 | 0.87 | HPGD (0.47) | USP2SMN1; SMN2GPR119NAMPTEPHX2 | |
| SCHEMBL28622796 | 0.87 | HPGD (0.47) | USP2SMN1; SMN2GPR119NAMPTEPHX2 | |
| SCHEMBL15769569 | 0.87 | HPGD (0.47) | USP2SMN1; SMN2GPR119NAMPTEPHX2 | |
| SCHEMBL21807018 | 0.87 | USP2 (0.49) | USP2SMN1; SMN2GPR119NAMPTEPHX2 | |
| Hydrochloric Acid SCHEMBL30803165 | 0.86 | HPGD (0.46) | USP2SMN1; SMN2GPR119NAMPTEPHX2 | |
| SCHEMBL1344048 | 0.85 | USP2 (0.50) | USP2SMN1; SMN2GPR119NAMPTEPHX2 | |
| SCHEMBL8217780 | 0.85 | USP2 (0.50) | USP2SMN1; SMN2GPR119NAMPTEPHX2 | |
| SCHEMBL16984146 | 0.85 | USP2 (0.50) | USP2SMN1; SMN2GPR119NAMPTEPHX2 | |
| SCHEMBL18838373 | 0.84 | HPGD (0.48) | USP2SMN1; SMN2GPR119NAMPTEPHX2 | |
| SCHEMBL24693756 | 0.84 | HPGD (0.48) | USP2SMN1; SMN2GPR119NAMPTEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12391675-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-20220089572-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY, INC. | 2022-03-24 | — | — | US | disclosed |
| EP-3911641-A1 | NLRP3 MODULATORS | Innate Tumor Immunity, Inc. (US) | 2021-11-24 | — | — | EP | disclosed |
| WO-2020150115-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY, INC. (US) | 2020-07-23 | — | — | WO | disclosed |
| WO-2012047703-A2 | CYCLOPROPYL-SPIRO-PIPERIDINES USEFUL AS SODIUM CHANNEL BLOCKERS | SCHERING CORPORATION (US) | 2012-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12391675-B2 | NLRP3 modulators | NLRP3, NLRP1, PYCARD | USP2 3741/4885SMN1; SMN2 4820/4885GPR119 475/4885 |
| US-20220089572-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, PYCARD | USP2 3741/4885SMN1; SMN2 4820/4885GPR119 475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.